

<b>Policy #</b>	<b>Policy Name</b>	<b>Brief Description of Policy Change</b>
UM ONC_1072	Myeloid Growth Factors	Annual Review
UM ONC_1138	Erythropoiesis Stimulating Agents (ESA)	Annual Review
UM ONC_1205	Havalen (eribulin)	Annual Review
UM ONC_1239	Pomalyst (pomalidomide)	Annual Review
UM ONC_1240	Synribo (omacetaxine)	Annual Review
UM ONC_1241	Iclusig (ponatinib)	Annual Review
UM ONC_1258	Gilotrif (afatinib)	Annual Review
UM ONC_1288	Fusilev (levoleucovorin)	Annual Review
UM ONC_1309	Iressa (gefitinib)	Annual Review
UM ONC_1312	Odomzo (sonidegib)	Annual Review
UM ONC_1327	Aliqopa (copanlisib)	Annual Review
UM ONC_1330	Besponsa (inotuzumab ozogamicin)	Annual Review
UM ONC_1334	Doptelet (avatrombopag)	Annual Review
UM ONC_1343	Mulpleta (lusutrombopag)	Annual Review
UM ONC_1346	Copiktra (duvelisib)	Annual Review
UM ONC_1348	Lumoxiti (moxetumomab pasudotox)	Annual Review
UM ONC_1360	Piqray (alpelisib)	Annual Review
UM ONC_1376	Oxbryta (voxelotor)	Annual Review
UM ONC_1410	Inqovi (decitabine and cedazuridine)	Annual Review
UM ONC_1416	Onureg (azacitidine oral)	Annual Review
UM ONC_1445	Topical and Intralesional Therapies	Annual Review
UM ONC_1457	Fyarro (intravenous sirolimus)	Annual Review
UM ONC_1461	Vonjo (pacritinib)	Annual Review
UM ONC_1463	Pluvicto (lutetium Lu 177 vipivotide tetraxetan)	Annual Review